Connection
Christine Walsh to CA-125 Antigen
This is a "connection" page, showing publications Christine Walsh has written about CA-125 Antigen.
|
|
Connection Strength |
|
 |
|
 |
|
0.276 |
|
|
|
-
Walsh CS, Kamrava M, Rogatko A, Kim S, Li A, Cass I, Karlan B, Rimel BJ. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS One. 2021; 16(6):e0252665.
Score: 0.185
-
Fleming ND, Cass I, Walsh CS, Karlan BY, Li AJ. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):249-52.
Score: 0.091